This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 23.86% and 4.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher Scientific (TMO) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Thermo Fisher (TMO) delivered earnings and revenue surprises of 17.50% and 11.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: LENSAR, Inc. (LNSR) Q1 Earnings Expected to Decline
by Zacks Equity Research
LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 3.45% and 2.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in LENSAR, Inc. (LNSR): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
LENSAR, Inc. (LNSR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LENSAR, Inc. (LNSR) Moves 13.5% Higher: Will This Strength Last?
by Zacks Equity Research
LENSAR, Inc. (LNSR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
LENSAR, Inc. (LNSR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 31.67% and 31.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Repro Med Systems, Inc. (KRMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 5.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 7.65%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -35% and 0.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
LENSAR, Inc. (LNSR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of -10.17% and 7.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will LENSAR, Inc. (LNSR) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.